R. Archer

发表

Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

S. Davis, M. Stevenson, J. Stevens, 2013, PharmacoEconomics.

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.

M. Stevenson, J. Hamilton, J. Stevens, 2018, Health technology assessment.

Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.

L. Preston, A. Brennan, R. Purshouse, 2013, Alcohol and alcoholism.

A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy

Marrissa Martyn-St James, P. Tappenden, A. Lobo, 2016, PharmacoEconomics.

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

P. Tappenden, A. Lobo, S. Ren, 2016, PharmacoEconomics.

Factors influencing the implementation of Global Polio Eradication Initiative in low- and middle-income countries: a qualitative evidence synthesis

A. Booth, C. Blackmore, R. Archer, 2019 .

Interventions to promote oral nutritional behaviours in people living with neurodegenerative disorders of the motor system: A systematic review.

P. Norman, T. Stavroulakis, C. Mcdermott, 2019, Clinical nutrition.

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

M. Stevenson, J. Stevens, A. Young, 2017, PharmacoEconomics.

Factors influencing the implementation of Global Polio Eradication Initiative in low- and middle-income countries: a qualitative evidence synthesis

A. Booth, C. Blackmore, R. Archer, 2019, Journal of Global Health Reports.

Factors affecting the successful implementation of Global Polio Eradication Initiative (GPEI) in low- and middle-income countries

A. Booth, C. Blackmore, R. Archer, 2020, Journal of global health.

Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis

S. Paisley, M. Stevenson, A. Binard, 2019, International Journal of Technology Assessment in Health Care.

The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate

M. Stevenson, A. Wailoo, J. Stevens, 2017, The Journal of Rheumatology.

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.

C. Carroll, P. Tappenden, A. Lobo, 2016, Health technology assessment.

Risk Prediction Models for Lung Cancer: A Systematic Review.

M. Teare, J. Stevens, R. Archer, 2016, Clinical lung cancer.

Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.

M. Stevenson, C. Littlewood, J. Stevens, 2014, Health technology assessment.

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review

S. Paisley, M. Stevenson, A. Wailoo, 2016, Health technology assessment.

ITERATIVE SIFTING IN THE SELECTION OF RESEARCH EVIDENCE: IMPLICATIONS FOR REVIEWS AND OTHER DECISION PROBLEMS

Rachel Archer, Suzy Paisley, Munira Essat, 2015, International Journal of Technology Assessment in Health Care.

Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

S. Davis, M. Stevenson, J. Stevens, 2013, PharmacoEconomics.

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review

S. Paisley, M. Stevenson, A. Wailoo, 2016, Health technology assessment.